Navigation Links
Regulus Announces Publication in Nature Communications Identifying miR-17 as a Promising Drug Target for ADPKD
Date:2/16/2017

LA JOLLA, Calif., Feb. 16, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Nature Communications has published an article entitled "microRNA-17 family promotes polycystic kidney disease progression through the modulation of mitochondrial metabolism." The article highlights research that identifies miR-17 as a target for the treatment of autosomal dominant polycystic kidney disease (ADPKD) and can be found on-line at http://www.nature.com/ncomms.

"This successful collaboration between Regulus scientists and academic investigators, most importantly, Dr. Vishal Patel and his team at UT Southwestern Medical Center, represents a major advance in our understanding of the pathophysiology of ADPKD. These results provide strong evidence that targeting miR-17 may provide therapeutic benefit in humans and supports our development program for RGLS4326 (anti-miR-17) for the treatment of ADPKD," said Dr. Timothy Wright, Regulus' Chief R&D Officer. "Regulus expects to file an IND for RGLS4326 in the second half of 2017."

About Autosomal Dominant Polycystic Kidney Disease (ADPKD)

ADPKD, caused by the mutations of PKD1 or PKD2, is among the most common monogenetic disorders and a leading genetic cause of end-stage renal disease. The clinical hallmark of this disease is the presence of numerous renal tubule-derived cysts. Excessive proliferation, a central pathological feature, fuels the relentless expansion of cysts, ultimately causing end-stage renal disease. ADPKD affects approximately 600,000 people in the US and 12.5 million people worldwide.

About Regulus

Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field. Regulus is advancing several programs in renal, hepatic and central nervous systems diseases, both independently and with our strategic alliance partners, Sanofi and AstraZeneca. Regulus maintains its corporate headquarters in La Jolla, CA. For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Regulus to undertake certain activities and accomplish certain, the projected timeline of clinical development activities, and expectations regarding future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics and biomarkers being discovered and developed by Regulus. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Regulus' financial position and programs are described in additional detail in Regulus filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/regulus-announces-publication-in-nature-communications-identifying-mir-17-as-a-promising-drug-target-for-adpkd-300408511.html


'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Regulus to Present at Upcoming Healthcare Conferences
2. Regulus Announces Continuation of RG-101 Clinical Hold
3. Regulus Announces New Drug Development Candidates
4. Regulus Announces Timing for Fourth Quarter and Year-End 2015 Financial Results Webcast and Conference Call
5. Regulus Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
6. Regulus Expands Development of RG-101 through Clinical Trial Collaboration with GSK
7. Regulus Announces Timing for Third Quarter 2015 Financial Results Webcast and Conference Call
8. Regulus to Present at the 2015 Wedbush PacGrow Healthcare Conference
9. Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights
10. Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call
11. Regulus Initiates Phase I Clinical Study of RG-012, a microRNA Therapeutic in Development for the Treatment of Alport Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):